Kyoto Trial to Evaluate the Safety and Efficacy of Tacrolimus in the iPSC-based Therapy for Parkinson's Disease

General Information

Description To evaluate the safety and efficacy of tacrolimus in patients with Parkinson's disease after transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors into the corpus striatum.
Clinical trials phase Phase 3
Start date (estimated) 2018-08-01
Clinical feature
Label Parkinson's Disease
Description A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.

Administrative Information

ICTRP weblink
Other study identifiers
Name UMIN000033565
Description JPRN-UMIN
Source weblink
Regulatory body approval
Public contact
First name Nobukatsu
Last name Sawamoto
Phone 075-751-3771
City Kyoto
Address freetext 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507
Sponsors Kyoto University Hospital

Cell Line


Recruitment Status Recruiting
Estimated number of participants 7